Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04964557 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 411
- Enrollment target
NCT04964557 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 411 participants.
The verdict
NCT04964557, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 411 participants
- Enrollment target
Study Summary
AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate safety, efficacy and tolerability of AZD8233.
Interventions
- DRUG Placebo
- DRUG AZD8233
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 411 participants |
| Start Date | 2021-07-07 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04964557
The ClinicalTrials.gov registry entry for NCT04964557 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04964557 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04964557 about?
NCT04964557 is a clinical study titled "A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia". AZD8233 is a PCSK9-targeted ASO for the reduction of circulating levels of LDL-C. This study aims to evaluate safety, efficacy and tolerability of AZD8233.
What is the current status of trial NCT04964557?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 411 participants. The study started on 2021-07-07. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT04964557?
The interventions under investigation include: Placebo (DRUG), AZD8233 (DRUG).
Who is sponsoring clinical trial NCT04964557?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.